Drug
Refametinib clinical trials
Also written RDEA119 and BAY86-9766.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
10 studies that test it; most in 2013 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 1
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses refametinib is read from its arms, and is right about nine times in ten.
Testing it · 10
- Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer PatientsCompletedPhase 1BayerNCT00610194Written as RDEA119
- Combination With Gemcitabine in Advanced Pancreatic CancerCompletedPhase 1/2BayerNCT01251640Written as BAY86-9766+Gemcitabine
- Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)CompletedPhase 2BayerNCT01915589Written as Refametinib (BAY86-9766)
- Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)CompletedPhase 2BayerNCT01915602Written as Refametinib (BAY86-9766)
- BAY86-9766 Plus Gemcitabine Phase I Study in AsianCompletedPhase 1BayerNCT01764828Written as Refametinib (BAY86-9766)
- Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic CancerTerminatedPhase 1BayerNCT02168777Written as Refametinib (BAY86-9766)
- Japanese BAY86-9766 Monotherapy Phase I StudyCompletedPhase 1BayerNCT01179295Written as BAY86-9766
- Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract AdenocarcinomaCompletedPhase 2Samsung Medical CenterNCT02346032Written as refametinib
- RDEA119 and Sorafenib Combination Dose Escalation StudyCompletedPhase 1/2BayerNCT00785226Written as RDEA119
- Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced CancerCompletedPhase 1BayerNCT01392521Written as Copanlisib + Refametinib (BAY86-9766)
Given in every arm · 1 — refametinib is usual care beside what is tested
Codes
What other systems call refametinib · ClinicalTrials.gg INT005512
- UNII (FDA) JPX07AFM0NREFAMETINIBConfirmed FDA, Wikidata
- Wikidata Q27088526refametinibConfirmed FDA, Wikidata
- NCI Thesaurus C74059RefametinibOne source FDA
- DrugBank DB06309One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | JPX07AFM0N | REFAMETINIB | Confirmed FDA, Wikidata |
| Wikidata | Q27088526 | refametinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C74059 | Refametinib | One source FDA |
| DrugBank | DB06309 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.